CytoDyn Inc CYDY

Healthcare Biotechnology

CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. It has studied leronlimab in multiple therapeutic areas, including infectious disease, oncology, and autoimmune conditions. The Company has conducted clinical trials of leronlimab as a viral entry inhibitor for human immunodeficiency virus (HIV), believed to competitively bind to the N-terminus and second extracellular loop of the CCR5 receptor. For immunology, the CCR5 receptor is believed to be implicated in immune-mediated illnesses such as Metabolic dysfunction-associated steatohepatitis. It has a joint development agreement with a third-party generative artificial intelligence (AI) drug discovery and development company to develop one or more longer-acting molecules.

OTCQB:CYDY - Post by User

CytoDyn Inc > WOW WTF?

<< Previous

Bullboard Posts

Next >>

Comment by Pandoraon Dec 29, 2022 4:09pm

123 Views

Post# 35195945

RE:RE:WOW WTF?

Seems like the market was right. Another nothing burger.
Offhand I would have to give these guys an 'F' for rating their ability to communicate.
We get an announcement about once a month and after each one the share price dumps.

Pandora wrote:
By the looks of price and volume it seems like expectations for today's update are a "zero". I hope it is a little bit better than that, or this is a write off, which many people have alraedy done. Update at 8 a.m. Pacific time.

<< Previous

Bullboard Posts

Next >>

POET increases production capacity to meet AI demand